智通财经网·2025-10-31 06:08Core Viewpoint - Chuangsheng Group-B (06628) experienced a significant stock price increase following positive clinical trial results for its partner Inhibrx Biosciences, Inc.'s drug ozekibart, which is aimed at treating advanced or metastatic, unresectable soft tissue sarcoma [1] Group 1: Stock Performance - Chuangsheng Group-B's stock rose nearly 10% during trading, closing up 4.75% at HKD 3.09, with a trading volume of HKD 4.006 million [1] Group 2: Clinical Research Results - Inhibrx Biosciences, Inc. announced positive primary results from a registrational clinical study of ozekibart, a DR5 agonistic antibody, comparing its efficacy against a placebo in patients with advanced or metastatic, unresectable soft tissue sarcoma [1] - Based on these results, Inhibrx plans to submit a marketing application for the soft tissue sarcoma indication to U.S. regulatory authorities by the end of June 2026 [1] Group 3: Development Rights - Chuangsheng Group holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan [1]